Idiopathic Membranous Nephropathy Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Idiopathic Membranous Nephropathy Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Idiopathic Membranous Nephropathy Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Idiopathic Membranous Nephropathy (IMN), historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy (IMN) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Discover Key Insights into the Idiopathic Membranous Nephropathy Market with DelveInsight’s In-Depth Report @ Idiopathic Membranous Nephropathy Market Size

 

Key Takeaways from the Idiopathic Membranous Nephropathy Market Report

• In November 2024:- National Institute of Allergy and Infectious Diseases (NIAID)- The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy.
• In 2023, the US accounted for ~40% of all Idiopathic Membranous Nephropathy prevalent cases in 7MM.
• Japan’s data suggests a relatively stable trend in the Idiopathic Membranous Nephropathy prevalence over the forecasted period of 2024-2034.
• Germany had the highest Idiopathic Membranous Nephropathy prevalence among EU4 and the UK, accounting for ~30% of cases, followed by the UK with ~20%, in 2023.
• In 2023, the PLA2R-specific cases in EU4 and the UK contributed ~75% in the 7MM.
• The leading Idiopathic Membranous Nephropathy Companies such as SynAct Pharma Aps, argenx, Shanghai Jiaolian Drug Research and Development Co., Ltd, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals, Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Alpine Immune Sciences, Inc., Walden Biosciences, and others.
• Promising Idiopathic Membranous Nephropathy Therapies such as WAL0921, povetacicept, Belimumab, Obinutuzumab, Methylprednisolone, Tacrolimus, and others.

 

Stay ahead in the Idiopathic Membranous Nephropathy Therapeutics Market with DelveInsight’s Strategic Report @ Idiopathic Membranous Nephropathy Market Outlook

 

Idiopathic Membranous Nephropathy Epidemiology Segmentation in the 7MM

• Total Idiopathic Membranous Nephropathy prevalent cases
• Idiopathic Membranous Nephropathy antigen-specific cases
• Total Idiopathic Membranous Nephropathy treated cases

 

Download the report to understand which factors are driving Idiopathic Membranous Nephropathy epidemiology trends @ Idiopathic Membranous Nephropathy Prevalence

 

Idiopathic Membranous Nephropathy Market Insights

Membranous nephropathy (MN) is an autoimmune disease caused by antibodies mostly directed to podocyte antigens and characterized by very high levels of protein in the urine, edema, hypoalbuminemia, and elevated serum lipids. MN is typically divided into primary MN (Idiopathic membranous nephropathy) when there is no underlying disease association and secondary MN when there is an underlying disease association such as autoimmune disease (most commonly lupus), malignancy, infection, or temporal association with the use of certain drugs. The short-term goal of treatment is to stop protein spillage completely (known as remission) or lower the amount of protein lost in the urine as much as possible. The less protein lost in the urine, the better the individual will do. The long-term treatment goals, including protein relapses in the urine and preventing the deterioration of kidney function.

  

Idiopathic Membranous Nephropathy Emerging Drugs

• GAZYVA (obinutuzumab): Hoffmann-La Roche
• SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals

 

Get In-Depth Knowledge on Idiopathic Membranous Nephropathy Market Trends and Forecasts with DelveInsight @ Idiopathic Membranous Nephropathy Treatment Market

 

Idiopathic Membranous Nephropathy Drugs Uptake

Idiopathic Membranous Nephropathy pipeline possesses some drugs in mid- and late stage developments to be approved in the near future. Expected launch of emerging therapies, such as GAZYVA (obinutuzumab) by Hoffmann-La Roche, MOR202 (felzartamab) by MorphoSys/HI-Bio, MOR202 (felzartamab) by MorphoSys/HI-Bio, BRUKINSA (zanubrutinib) by BeiGene and others shall further create a positive impact on the market.

 

Scope of the Idiopathic Membranous Nephropathy Market Report

• Coverage- 7MM
• Idiopathic Membranous Nephropathy Companies- SynAct Pharma Aps, argenx, Shanghai Jiaolian Drug Research and Development Co., Ltd, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals, Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Alpine Immune Sciences, Inc., Walden Biosciences, and others.
• Idiopathic Membranous Nephropathy Therapies- WAL0921, povetacicept, Belimumab, Obinutuzumab, Methylprednisolone, Tacrolimus, and others.
• Idiopathic Membranous Nephropathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Idiopathic Membranous Nephropathy Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Membranous Nephropathy Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Idiopathic Membranous Nephropathy Market Report @ Idiopathic Membranous Nephropathy Market Drivers and Barriers

 

Table of Content

1. Key Insights

2. Report Introduction

3. Idiopathic Membranous Nephropathy (IMN) Market Overview at a Glance

4. Methodology

5. Executive Summary of IMN

6. Key Events

7. Disease Background and Overview

8. Treatment and Management

9. Epidemiology and Patient Population

10. Patient Journey

11. Emerging Therapies

12. Market Analysis

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/